ABBV-295 vs MET-233i

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

ABBV-295

Developed by AbbVie under a licence from Gubra

Phase 2 in Obesitypeptide
Weak signal

NCT06144684 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07514260 (registry estimate)

Reported efficacy

Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)

Result source: NCT06144684

MET-233i

Developed by Pfizer and partners

Phase 1/2 in Obesitypeptide
Weak signal

NCT07022977 · Phase 1 · completed

A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.

Next expected readout: January 2027 · NCT07725809 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointABBV-295MET-233i
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

ABBV-295
—Not reported
MET-233i
—Not reported

Weight loss of 5% or more

ABBV-295
—Not reported
MET-233i
—Not reported

Weight loss of 10% or more

ABBV-295
—Not reported
MET-233i
—Not reported

Waist circumference, change (cm)

ABBV-295
—Not reported
MET-233i
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ABBV-295: no structured comparison results are available for Obesity.

MET-233i: no structured comparison results are available for Obesity.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · MET-233i's landscape